Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
Vial Logo

Updates

Search
All Resources
Press Releases
Videos

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.

Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.

Load More

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.

Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.